Vivoryon Therapeutics NV banner

Vivoryon Therapeutics NV
AEX:VVY

Watchlist Manager
Vivoryon Therapeutics NV Logo
Vivoryon Therapeutics NV
AEX:VVY
Watchlist
Price: 1.32 EUR -2.22% Market Closed
Market Cap: €39.1m

Vivoryon Therapeutics NV
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Vivoryon Therapeutics NV
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Vivoryon Therapeutics NV
AEX:VVY
EPS (Diluted)
€0
CAGR 3-Years
-8%
CAGR 5-Years
-15%
CAGR 10-Years
10%
BioNTech SE
NASDAQ:BNTX
EPS (Diluted)
-€4
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
EPS (Diluted)
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
EPS (Diluted)
-€1
CAGR 3-Years
N/A
CAGR 5-Years
18%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
EPS (Diluted)
€0
CAGR 3-Years
24%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
EPS (Diluted)
-€7
CAGR 3-Years
-81%
CAGR 5-Years
-99%
CAGR 10-Years
N/A
No Stocks Found

Vivoryon Therapeutics NV
Glance View

Market Cap
39.1m EUR
Industry
Biotechnology

The company is headquartered in Halle, Sachsen-Anhalt and currently employs 16 full-time employees. The company went IPO on 2014-10-27.

VVY Intrinsic Value
Not Available

See Also

What is Vivoryon Therapeutics NV's EPS (Diluted)?
EPS (Diluted)
-0.8 EUR

Based on the financial report for Dec 31, 2024, Vivoryon Therapeutics NV's EPS (Diluted) amounts to -0.8 EUR.

What is Vivoryon Therapeutics NV's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
10%

Over the last year, the EPS (Diluted) growth was 29%. The average annual EPS (Diluted) growth rates for Vivoryon Therapeutics NV have been -8% over the past three years , -15% over the past five years , and 10% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett